Peel Hunt Increases Puretech Health (PRTC) Price Target to GBX 313

Puretech Health (LON:PRTC) had its price objective hoisted by stock analysts at Peel Hunt from GBX 302 ($4.10) to GBX 313 ($4.24) in a research note issued on Friday. The firm presently has a “buy” rating on the stock. Peel Hunt’s price objective would indicate a potential upside of 71.51% from the company’s current price.

Several other research firms have also recently issued reports on PRTC. Jefferies Group restated a “buy” rating on shares of Puretech Health in a research report on Friday, November 17th. N+1 Singer restated a “buy” rating on shares of Puretech Health in a research report on Thursday, November 30th. Liberum Capital restated a “buy” rating and set a GBX 248 ($3.36) price objective on shares of Puretech Health in a research report on Friday. Finally, Numis Securities raised their price objective on shares of Puretech Health from GBX 207 ($2.81) to GBX 233 ($3.16) and gave the stock a “buy” rating in a research report on Thursday, November 30th. Five investment analysts have rated the stock with a buy rating, Puretech Health presently has an average rating of “Buy” and an average target price of GBX 255 ($3.46).

Puretech Health (LON PRTC) traded up GBX 3 ($0.04) during trading on Friday, reaching GBX 182.50 ($2.47). 109,465 shares of the company traded hands, compared to its average volume of 78,873. Puretech Health has a 52-week low of GBX 110 ($1.49) and a 52-week high of GBX 183 ($2.48). The firm has a market capitalization of $442.41 and a PE ratio of -1,013.89.

WARNING: “Peel Hunt Increases Puretech Health (PRTC) Price Target to GBX 313” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/27/peel-hunt-increases-puretech-health-prtc-price-target-to-gbx-313.html.

About Puretech Health

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.

Analyst Recommendations for Puretech Health (LON:PRTC)

Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply